
- Oncology NEWS International Vol 17 No 3
- Volume 17
- Issue 3
Renal ca surgery often determined by doctors’ practice style
A new study shows that the type of surgery a patient with renal cancer receives depends more on the surgeon’s preference than on the patient’s tumor size, demographic characteristics, or general medical health (Miller et al: Cancer, published online March 10, 2008, DOI: 10.1002/cncr.23372).
A new study shows that the type of surgery a patient with renal cancer receives depends more on the surgeon’s preference than on the patient’s tumor size, demographic characteristics, or general medical health (Miller et al: Cancer, published online March 10, 2008, DOI: 10.1002/cncr.23372).
The findings suggest that patients with renal cancer often may not be receiving the most appropriate surgical care, said David Miller, MD, and colleagues from UCLA.
To investigate the potential barriers to adoption of partial nephrectomy and renal laparoscopy, Dr. Miller and his colleagues reviewed SEER and Medicare data to identify Medicare beneficiaries with localized renal cancer diagnosed between 1997 and 2002, determine the type of surgery received by each patient, and identify the primary surgeon for each case.
They found 611 patients who underwent partial nephrectomy and 4,872 who had radical nephrectomy, 515 of which were performed laparoscopically.
After taking into consideration factors including patient demographics, comorbidity, tumor size, and volume of surgeries done by each surgeon, the investigators found considerable variation among surgeons in the type of surgery they performed-an 18.1% variance for partial nephrectomy and a 37.4% variance for laparoscopy.
Factors based on surgeons’ practice style contributed more to these variances than did patient characteristics.
The authors concluded that “for many older patients with kidney cancer, the surgery provided may depend more on their surgeon’s practice style than on the characteristics of the patient and his or her disease.”
Articles in this issue
over 17 years ago
Recentin headed to phase III in first-line colon caover 17 years ago
Topo 2 alpha test FDA approvedover 17 years ago
RFA provides sustained pain relief in osteoid osteomaover 17 years ago
Partial nephrectomy underutilized for small renal tumorsover 17 years ago
Most older men with early-stage cancer can avoid treatmentover 17 years ago
SERM reduces ADT side effectsover 17 years ago
New serum biomarker appears to detect colon cancerover 17 years ago
Hypofractionated IMRT does not increase sexual side effectsover 17 years ago
Surface mapping aligns patients for external beam PBIover 17 years ago
Is benefit of trastuzumab limited to first 18 months?Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.